Results 161 to 170 of about 144,049 (286)
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando +17 more
wiley +1 more source
The alpha and beta diversity of the nasal microbiome differed among children with allergic rhinitis (AR), nonallergic rhinitis (NAR), and healthy controls (HCs). Compared to HC, AR had more Escherichia‐Shigella, Negativicoccus, and Campylobacter, while NAR had more Dolosigranulum and fewer Enterobacteriaceae.
Kantima Kanchanapoomi +6 more
wiley +1 more source
Breast milk miRNAs and their potential role in the development of atopy in infants. [PDF]
Porębska A +4 more
europepmc +1 more source
Inflammatory Shift in Chronic Rhinosinusitis Amidst Guangzhou's Urbanization (2000–2018)
ABSTRACT Background Chronic rhinosinusitis (CRS) exhibits temporal and geographic diversity in pathological endotypes with progressive eosinophilic infiltration, while the underlying causes remain unclear. Current pathological endotypes determination relies on mean cell count per high‐power field, requiring accuracy optimization.
Ning Kang +16 more
wiley +1 more source
Exhaled breath condensate thymic stromal lymphopoietin, OX40 ligand, eotaxin, and interleukin-23 in children with atopic dermatitis and persistent wheeze. [PDF]
Geyik C +5 more
europepmc +1 more source
ABSTRACT Atopic dermatitis (AD) is a chronic inflammatory dermatitis underpinned by Type 2 inflammation driven by cytokines such as IL‐4 and IL‐13. It is characterized by skin barrier dysfunction, Th2 immune deviation, and pruritus. While biologics and oral Janus kinase (JAK) inhibitors demonstrate high therapeutic efficacy by targeting cytokines that ...
Gaku Tsuji +7 more
wiley +1 more source
Targeted Systemic Therapies for Atopic Dermatitis in Australia: A Narrative Review
ABSTRACT Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease estimated to affect approximately 30% of children and 10%–15% of adults in Australia. Of those with this condition, one in five is estimated to have moderate‐to‐severe disease.
Diana Rubel +5 more
wiley +1 more source
Reframing Eczema: Th2-Skewed Contact Sensitization, Atopy Patch Testing, and Systemic Contact Dermatitis. [PDF]
Jacob SE, Scheman A, Nedorost S.
europepmc +1 more source
Sociodemographic Disparities in Pediatric Dermatological Conditions: Insights From the 2019 Global Burden of Disease Project. [PDF]
Mackenzie E +5 more
europepmc +1 more source

